Evidence map›Paper›PMID 39121159›Full record

ArticlePLoS neglected tropical diseases2024

Unveiling the Enigmatic nature of six neglected Amazonian Leishmania (Viannia) species using the hamster model: Virulence, Histopathology and prospection of LRV1.

Rodrigo Pedro Soares, Igor Campos Fontes, Felipe Dutra-Rêgo, Jeronimo Nunes Rugani, Paulo Otávio L Moreira, Vânia Lúcia Ribeiro da Matta, Gabriela Venícia Araujo Flores, Carmen Maria Sandoval Pacheco, Andrey José de Andrade, Magda Clara Vieira da Costa-Ribeiro and 2 more

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Journal of parasitology research · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rodrigo Pedro SoaresGrupo Biotecnologia Aplicada ao Estudo de Patógenos (BAP), Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ), Belo Horizonte, Minas Gerais, Brazil.ORCID 0000-0002-7966-3629
Igor Campos FontesGrupo Biotecnologia Aplicada ao Estudo de Patógenos (BAP), Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ), Belo Horizonte, Minas Gerais, Brazil.
Felipe Dutra-RêgoGrupo Biotecnologia Aplicada ao Estudo de Patógenos (BAP), Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ), Belo Horizonte, Minas Gerais, Brazil.
Jeronimo Nunes RuganiGrupo Biotecnologia Aplicada ao Estudo de Patógenos (BAP), Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ), Belo Horizonte, Minas Gerais, Brazil.
Paulo Otávio L MoreiraGrupo Biotecnologia Aplicada ao Estudo de Patógenos (BAP), Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ), Belo Horizonte, Minas Gerais, Brazil.
Vânia Lúcia Ribeiro da MattaLaboratório de Patologia das Moléstias Infecciosas, Departamento de Patologia, Faculdade de Medicina, Universidade de São Paulo (USP), São Paulo, São Paulo, Brazil.
Gabriela Venícia Araujo FloresLaboratório de Patologia das Moléstias Infecciosas, Departamento de Patologia, Faculdade de Medicina, Universidade de São Paulo (USP), São Paulo, São Paulo, Brazil.
Carmen Maria Sandoval PachecoLaboratório de Patologia das Moléstias Infecciosas, Departamento de Patologia, Faculdade de Medicina, Universidade de São Paulo (USP), São Paulo, São Paulo, Brazil.
Andrey José de AndradeLaboratório de Parasitologia Molecular, Departamento de Patologia Básica, Setor de Ciências Biológicas, Universidade Federal do Paraná (UFPR), Curitiba, Paraná, Brazil.
Magda Clara Vieira da Costa-RibeiroLaboratório de Parasitologia Molecular, Departamento de Patologia Básica, Setor de Ciências Biológicas, Universidade Federal do Paraná (UFPR), Curitiba, Paraná, Brazil.
Jeffrey Jon ShawDepartamento de Parasitologia, Instituto de Ciências Biomédicas, Universidade de São Paulo (USP), São Paulo, São Paulo, Brazil.
Márcia Dalastra LaurentiLaboratório de Patologia das Moléstias Infecciosas, Departamento de Patologia, Faculdade de Medicina, Universidade de São Paulo (USP), São Paulo, São Paulo, Brazil.ORCID 0000-0002-1080-2440

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 305238/2023-0Conselho Nacional de Desenvolvimento Científico e Tecnológico 308817/2021-4
6 · The paper itself

Abstract

American tegumentary leishmaniasis (ATL) is highly endemic in the Amazon basin and occurs in all South American countries, except Chile and Uruguay. Most Brazilian ATL cases are due to Leishmania (Viannia) braziliensis, however other neglected Amazonian species are being increasingly reported. They belong to the subgenus L. (Viannia) and information on suitable models to understand immunopathology are scarce. Here, we explored the use of the golden hamster Mesocricetus auratus and its macrophages as a model for L. (Viannia) species. We also studied the interaction of parasite glycoconjugates (LPGs and GIPLs) in murine macrophages. The following strains were used: L. (V.) braziliensis (MHOM/BR/2001/BA788), L. (V.) guyanensis (MHOM/BR/85/M9945), L. (V.) shawi (MHOM/BR/96/M15789), L. (V.) lindenbergi (MHOM/BR/98/M15733) and L. (V.) naiffi (MDAS/BR/79/M5533). In vivo infections were initiated by injecting parasites into the footpad and were followed up at 20- and 40-days PI. Parasites were mixed with salivary gland extract (SGE) from wild-captured Nyssomyia neivai prior to in vivo infections. Animals were euthanized for histopathological evaluation of the footpads, spleen, and liver. The parasite burden was evaluated in the skin and draining lymph nodes. In vitro infections used resident peritoneal macrophages and THP-1 monocytes infected with all species using a MOI (1:10). For biochemical studies, glycoconjugates (LPGs and GIPLs) were extracted, purified, and biochemically characterized using fluorophore-assisted carbohydrate electrophoresis (FACE). They were functionally evaluated after incubation with macrophages from C57BL/6 mice and knockouts (TLR2-/- and TLR4-/-) for nitric oxide (NO) and cytokine/chemokine production. All species, except L. (V.) guyanensis, failed to generate evident macroscopic lesions 40 days PI. The L. (V.) guyanensis lesions were swollen but did not ulcerate and microscopically were characterized by an intense inflammatory exudate. Despite the fact the other species did not produce visible skin lesions there was no or mild pro-inflammatory infiltration at the inoculation site and parasites survived in the hamster skin/lymph nodes and even visceralized. Although none of the species caused severe disease in the hamster, they differentially infected peritoneal macrophages in vitro. LPGs and GIPLs were able to differentially trigger NO and cytokine production via TLR2/TLR4 and TLR4, respectively. The presence of a sidechain in L. (V.) lainsoni LPG (type II) may be responsible for its higher proinflammatory activity. After Principal Component analyses using all phenotypic features, the clustering of L. (V.) lainsoni was separated from all the other L. (Viannia) species. We conclude that M. auratus was a suitable in vivo model for at least four dermotropic L. (Viannia) species. However, in vitro studies using peritoneal cells are a suitable alternative for understanding interactions of the six L. (Viannia) species used here. LRV1 presence was found in L. (V.) guyanensis and L. (V.) shawi with no apparent correlation with virulence in vitro and in vivo. Finally, parasite glycoconjugates were able to functionally trigger various innate immune responses in murine macrophages via TLRs consistent with their inflammatory profile in vivo.

Indexed as

Disease Models, AnimalLeishmaniaMacrophagesMesocricetusAnimalsCricetinaeFemaleGlycoconjugatesLeishmaniasis, CutaneousMaleMiceVirulenceGlycoconjugates

Identifiers

PMID39121159
PMCPMC11315283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.